Xerostomia (Dry Mouth Disease) Therapeutics Market

Market Overview:

The global xerostomia (dry mouth disease) therapeutics market size reached US$ 739.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 985.0 Million by 2032, exhibiting a growth rate (CAGR) of 3.13% during 2024-2032.

Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer’s disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function. 

Xerostomia (Dry Mouth Disease) Therapeutics Market Trends:

The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren’s syndrome, Alzheimer’s diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth. Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeutics market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type and distribution channel.

Breakup by Type:

• Artificial Saliva/Saliva Substitutes
• Salivary Stimulants
   

Breakup by Drug Type:

• OTC
• Prescription
   

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).

Report Coverage: